Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13


Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer.

Owen DH, Wei L, Bertino EM, Edd T, Villalona-Calero MA, He K, Shields PG, Carbone DP, Otterson GA.

Clin Lung Cancer. 2018 Aug 22. pii: S1525-7304(18)30202-X. doi: 10.1016/j.cllc.2018.08.008. [Epub ahead of print]


The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer.

Miller ED, Fisher JL, Haglund KE, Grecula JC, Xu-Welliver M, Bertino EM, He K, Shields PG, Carbone DP, Williams TM, Otterson GA, Bazan JG.

J Thorac Oncol. 2018 Mar;13(3):426-435. doi: 10.1016/j.jtho.2017.11.135. Epub 2018 Jan 8.


Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy.

Shukuya T, Patel S, Shane-Carson K, He K, Bertino EM, Shilo K, Otterson GA, Carbone DP.

J Thorac Oncol. 2018 Feb;13(2):e17-e19. doi: 10.1016/j.jtho.2017.09.1962. Epub 2017 Oct 5. No abstract available.


Tumor spread through air space (STAS) is an important predictor of clinical outcome in stage IA lung adenocarcinoma.

Chen HZ, Bertino EM, He K.

J Thorac Dis. 2017 Aug;9(8):2283-2285. doi: 10.21037/jtd.2017.07.69. No abstract available.


Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies.

Shukuya T, Mori K, Amann JM, Bertino EM, Otterson GA, Shields PG, Morita S, Carbone DP.

J Thorac Oncol. 2016 Nov;11(11):1927-1939. doi: 10.1016/j.jtho.2016.07.017. Epub 2016 Aug 3.


A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.

Bertino EM, McMichael EL, Mo X, Trikha P, Davis M, Paul B, Grever M, Carson WE, Otterson GA.

Mol Cancer Ther. 2016 Sep;15(9):2244-50. doi: 10.1158/1535-7163.MCT-15-0879. Epub 2016 Jul 25.


Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.

Bertino EM, Williams TM, Nana-Sinkam SP, Shilo K, Chatterjee M, Mo X, Rahmani M, Phillips GS, Villalona-Calero MA, Otterson GA.

Clin Lung Cancer. 2015 Nov;16(6):466-74. doi: 10.1016/j.cllc.2015.05.004. Epub 2015 May 13.


Consensus guidelines for the management and treatment of neuroendocrine tumors.

Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC; North American Neuroendocrine Tumor Society.

Pancreas. 2013 May;42(4):557-77. doi: 10.1097/MPA.0b013e31828e34a4.


A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).

Bertino EM, Bekaii-Saab T, Fernandez S, Diasio RB, Karim NA, Otterson GA, Villalona-Calero MA.

Lung Cancer. 2013 Jan;79(1):27-32. doi: 10.1016/j.lungcan.2012.09.013. Epub 2012 Oct 16.


Romidepsin: a novel histone deacetylase inhibitor for cancer.

Bertino EM, Otterson GA.

Expert Opin Investig Drugs. 2011 Aug;20(8):1151-8. doi: 10.1517/13543784.2011.594437. Epub 2011 Jun 24. Review.


Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer.

Bertino EM, Otterson GA.

Lung Cancer. 2010 Dec;70(3):233-46. doi: 10.1016/j.lungcan.2010.08.018. Review.


Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer.

Bertino EM, Ramaswamy B.

Breast Cancer (Dove Med Press). 2010 May 24;2:13-23. Review.


Pulmonary neuroendocrine/carcinoid tumors: a review article.

Bertino EM, Confer PD, Colonna JE, Ross P, Otterson GA.

Cancer. 2009 Oct 1;115(19):4434-41. doi: 10.1002/cncr.24498. Review.

Supplemental Content

Loading ...
Support Center